This study is placebo controlled, double blind, randomised, two arm dose escalation of a new product for specific immunotherapy in cat allergic patients

Inclusion criteria:

• History and subjective symptoms of cat dander allergy including cat specific allergic rhinitis
• Age 18 to 65 years
• Positive reaction to at least one concentration of cat dander allergen in skin prick test, intradermal provocation test and nasal provocation test

Exclusion criteria:

• Chronic infectious disease
• Acute infections
• Episode of non-allergic rhinitis within the last 4 weeks
• Use of allergen known to predict anaphylactic reactions
• Treatment with any other investigational drug within 3 months before trial entry
• Vaccination within the last week
• Nasal surgery within the last 8 weeks
• Progressive fatal disease
• Drug or alcohol abuse within the last 5 years
• Cat ownership
• A history of significant cardiac insufficiency (NYHA stage III-IV)
• Coexisting severe disease, e.g. cardiovascular diseases
• Acute or history of obstructive respiratory insufficiency ( FEV1 <70%)
• Hepatic insufficiency
• Relevant anaemia (as judged by investigator)
• Blood donation within the last 30 days or intended blood donation (during the study or 30 days after participation)
• Pregnancy or breast feeding
• Sexually active woman of childbearing potential not actively practicing birth control by using a medically accepted device or therapy
• Lack of compliance or other sililar reason, that the investigator believes, precludes satisfactory participation in the study
• Systemic glucocorticoid therapy
• Allergic asthma and chronic medication with steroids at doses exceeding 200ug/day Treatment with ATII antagonists, B-blocker, ACE inhibitors